Home » Stocks » SLDB

Solid Biosciences Inc. (SLDB)

Stock Price: $4.81 USD -0.10 (-2.04%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
After-hours: $4.75 -0.06 (-1.25%) Apr 20, 7:40 PM
Market Cap 529.77M
Revenue (ttm) n/a
Net Income (ttm) -88.29M
Shares Out 110.14M
EPS (ttm) -1.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 20
Last Price $4.81
Previous Close $4.91
Change ($) -0.10
Change (%) -2.04%
Day's Open 4.83
Day's Range 4.74 - 4.97
Day's Volume 727,784
52-Week Range 1.93 - 11.58

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

These drugmaker stocks may have been hammered down to bargain-bin prices.

Other stocks mentioned: FREQ, SRRK
1 week ago - The Motley Fool

CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), ...

3 weeks ago - GlobeNewsWire

Solid Biosciences (SLDB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

3 weeks ago - Zacks Investment Research

CAMBRIDGE, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), ...

4 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), ...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), ...

1 month ago - GlobeNewsWire

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Solid Biosciences' (SLDB) lead gene therapy candidate achieves positive improvements in DMD patients. However, it fails to cheer investors.

1 month ago - Zacks Investment Research

Investors appear to be skeptical about the biotech's latest clinical update.

1 month ago - The Motley Fool

Solid Biosciences Inc (NASDAQ: SLDB) reported interim functional, biomarker data, and patient-reported outcome measures from its ongoing IGNITE Phase 1/2 trial of its lead gene therapy candidate, SGT-00...

1 month ago - Benzinga

- Interim data from six patients provide evidence of a potential benefit of SGT-001 in functional endpoints of North Star Ambulatory Assessments (NSAA), 6-minute walk test (6MWT), pulmonary function tes...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), ...

1 month ago - GlobeNewsWire

-Adding senior level experience to help advance programs for Duchenne muscular dystrophy-

1 month ago - GlobeNewsWire

- IGNITE DMD Principal Investigator, Dr. Barry Byrne, to present efficacy and safety data from the ongoing IGNITE DMD trial on Thursday, March 18-

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), t...

2 months ago - GlobeNewsWire

Blame it on Sarepta.

3 months ago - The Motley Fool

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), t...

3 months ago - GlobeNewsWire

Tv Therapeutics (NASDAQ: VTVT) shares were trading higher on Friday after the company said its Phase 2 Simplici-T1 study of TTP399 achieved the primary objective of a statistically significant reduction...

Other stocks mentioned: VTVT, SLS
4 months ago - Benzinga

CAMBRIDGE, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), t...

4 months ago - GlobeNewsWire

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

SLDB is recovering from clinical holds placed on lead drug candidate SGT-001 for DMD. They entered a new deal with Ultragenyx, and have cash for the next year.

5 months ago - Seeking Alpha

Solid Biosciences' (SLDB) CEO Ilan Ganot on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Solid Biosciences??? (SLDB) reports wider than expected loss in the third quarter of 2020.

5 months ago - Zacks Investment Research

–IGNITE DMD clinical trial expected to resume dosing in the first quarter of 2021 –

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), t...

5 months ago - GlobeNewsWire

Solid Biosciences (SLDB) will provide updates on its lead pipeline candidate,SGT-001, along with others when it releases third-quarter 2020 results.

5 months ago - Zacks Investment Research

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), t...

6 months ago - GlobeNewsWire

Solid Biosciences Inc. (NASDAQ: SLDB) shares more than doubled on Thursday after the company announced a key update from the U.S. Food and Drug Administration (FDA). Essentially, the agency has decided ...

6 months ago - 24/7 Wall Street

– Modifications to IGNITE DMD trial protocol and improvements to manufacturing processes enable continued program development –

6 months ago - GlobeNewsWire

NEW YORK, July 29, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Solid Biosciences Inc. ("Solid Biosciences" or the "Company") (NASDAQ: SLDB).

8 months ago - PRNewsWire

CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, today anno...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced ...

10 months ago - GlobeNewsWire

Solid Biosciences (SLDB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for May 13th

Other stocks mentioned: IDCC, ISEE, MRSN
11 months ago - Zacks Investment Research

CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced t...

11 months ago - GlobeNewsWire

RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.

Other stocks mentioned: ATRA, BHVN, CBAY, MRNS, PTCT, TBIO
11 months ago - InvestorPlace

Smith to Deepen Strategic Leadership and Complement Commercial, Operational and Financial Expertise of the Board

1 year ago - GlobeNewsWire

The company announced plans to slash its head count and go all in on a single gene therapy. Is that wise or stubborn?

1 year ago - The Motley Fool

CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced changes to its organizational structure to create a leaner company focused on advancing SGT-00...

1 year ago - GlobeNewsWire

Early data for its side-effect-ridden gene therapy SGT-001 doesn't look very promising.

1 year ago - The Motley Fool

Solid Biosciences Inc. (NASDAQ: SLDB) shares jumped on Wednesday after the firm provided an update from its midstage study in Duchenne muscular dystrophy (DMD).

1 year ago - 24/7 Wall Street

Solid Biosciences Inc (NASDAQ: SLDB) shares are advancing strongly Wednesday following on an update on its clinical development program for its SGT-001, its gene transfer investigational candidate for D...

1 year ago - Benzinga

Shares of Solid Biosciences Inc. SLDB, +7.99% gained 22% in premarket trading on Wednesday after the company said two patients who received doses of its experimental Duchenne muscular dystrophy (DMD) tr...

1 year ago - Market Watch

- Demonstrated expression of SGT-001 microdystrophin and nNOS function provide evidence that SGT-001 has the potential to provide therapeutic benefit for patients with Duchenne

1 year ago - GlobeNewsWire

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Solid Biosciences: Amid The Difficulty Is An Opportunity

1 year ago - Seeking Alpha

A clinical trial evaluating the company's lead drug candidate was placed on a clinical hold -- for the third time.

1 year ago - The Motley Fool

Solid Biosciences Inc (NASDAQ: SLDB) shares pulled back to all-time lows Tuesday after the company said its lead gene therapy candidate to treat Duchenne muscular dystrophy has been placed on clinical h...

1 year ago - Benzinga

Company to hold conference call at 8:30 AM ET today Company to hold conference call at 8:30 AM ET today

1 year ago - GlobeNewsWire

About SLDB

Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 prot... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jan 26, 2018
Stock Exchange
NASDAQ
Ticker Symbol
SLDB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for SLDB stock is "Hold." The 12-month stock price forecast is 11.17, which is an increase of 132.22% from the latest price.

Price Target
$11.17
(132.22% upside)
Analyst Consensus: Hold